JPMorgan analyst John Royall upgraded Delek US to Neutral from Underweight with a price target of $26, up from $23. The company has generated consolidated EBITDA of $45M on a value-neutral basis by reinvesting high multiple proceeds into lower multiple acquisitions and organic projects, the analyst tells investors in a research note. The firm says Delek’s efforts have created consolidated value, warranting an upgrade to Neutral
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DK: